Related Experiment Video
Updated: Jul 2, 2025

05:35
Author Spotlight: Developing a Point-of-Care Hemoglobin Estimation Method for Anemia Management
Published on: January 19, 2024
800
Expert recommendations for the management of iron deficiency in patients with heart failure in Asia
David Kheng Leng Sim1, Sanjay Mittal2, Jian Zhang3
1Department of Cardiology, National Heart Centre Singapore, Singapore.
International Journal of Cardiology
|February 21, 2024
Summary
Iron deficiency is common in heart failure (HF) and impacts quality of life. Asian expert recommendations guide screening, intravenous iron treatment, and monitoring for HF patients to improve care.
Area of Science:
- Cardiology
- Internal Medicine
- Pharmacology
Background:
- Iron deficiency is a frequent comorbidity in heart failure (HF), negatively impacting quality of life and exercise capacity.
- It increases hospitalization risk in HF patients, irrespective of anemia.
- Established international guidelines for iron deficiency management in HF exist, but are less developed in Asia.
Purpose of the Study:
- To provide expert guidance for managing iron deficiency in heart failure patients within the Asian community.
- To address the limited established guidelines and practical application of management strategies in the region.
Main Methods:
- A panel of cardiologists from various Asian countries convened to discuss and formulate recommendations.
- Expert opinions were gathered on screening, diagnosis, treatment, and monitoring of iron deficiency in HF.
Main Results:
- Recommendations include screening all heart failure with reduced ejection fraction patients for iron deficiency.
- Intravenous iron treatment is advised for iron-deficient HF patients, with annual or biannual monitoring.
- Identified barriers include low physician awareness, lack of reimbursement, and inadequate facilities for IV iron administration.
Conclusions:
- These expert recommendations offer a structured framework for managing iron deficiency in Asian heart failure patients.
- Implementation of these guidelines can help overcome regional barriers and improve patient outcomes.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
431
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
431
Heart Failure Drugs: Inotropic Agents
588
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
588
Heart Failure Drugs: Diuretics
381
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
381
Heart Failure Drugs: β-Blockers
340
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
340
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K

